



Trojan Horse Transit Contributes to Blood-Brain Barrier Crossing of a Eukaryotic Pathogen

Felipe H. Santiago-Tirado,^a Michael D. Onken,^b John A. Cooper,^b Robyn S. Klein,^c Tamara L. Doering^a

Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USA^a; Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, Missouri, USA^b; Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA^c

ABSTRACT The blood-brain barrier (BBB) protects the central nervous system (CNS) by restricting the passage of molecules and microorganisms. Despite this barrier, however, the fungal pathogen *Cryptococcus neoformans* invades the brain, causing a meningoencephalitis that is estimated to kill over 600,000 people annually. Cryptococcal infection begins in the lung, and experimental evidence suggests that host phagocytes play a role in subsequent dissemination, although this role remains ill defined. Additionally, the disparate experimental approaches that have been used to probe various potential routes of BBB transit make it impossible to assess their relative contributions, confounding any integrated understanding of cryptococcal brain entry. Here we used an *in vitro* model BBB to show that a “Trojan horse” mechanism contributes significantly to fungal barrier crossing and that host factors regulate this process independently of free fungal transit. We also, for the first time, directly imaged *C. neoformans*-containing phagocytes crossing the BBB, showing that they do so via transendothelial pores. Finally, we found that Trojan horse crossing enables CNS entry of fungal mutants that cannot otherwise traverse the BBB, and we demonstrate additional intercellular interactions that may contribute to brain entry. Our work elucidates the mechanism of cryptococcal brain invasion and offers approaches to study other neuropathogens.

IMPORTANCE The fungal pathogen *Cryptococcus neoformans* invades the brain, causing a meningoencephalitis that kills hundreds of thousands of people each year. One route that has been proposed for this brain entry is a Trojan horse mechanism, whereby the fungus crosses the blood-brain barrier (BBB) as a passenger inside host phagocytes. Although indirect experimental evidence supports this intriguing mechanism, it has never been directly visualized. Here we directly image Trojan horse transit and show that it is regulated independently of free fungal entry, contributes to cryptococcal BBB crossing, and allows mutant fungi that cannot enter alone to invade the brain.

Fungal infections of the central nervous system (CNS) cause 1.5 million deaths every year worldwide (1). The major cause is the basidiomycete *Cryptococcus neoformans* (2), a ubiquitous environmental yeast (3, 4). Inhalation of this pathogen leads to pneumonia, which in healthy people either is resolved or remains asymptomatic. In the setting of immunocompromise, however, *C. neoformans* disseminates, with specific tropism for the CNS. To enter the brain, *C. neoformans* must cross the blood-brain barrier (BBB), which protects the CNS from chemical and infectious damage (5). Potential routes of cryptococcal entry include (i) direct fungal interactions with brain endothelial cells, leading to endocytosis and subsequent transcytosis of free fungi (6–9); (ii) disruption of BBB endothelial cell junctions, allowing paracellular passage of

Received 14 December 2016 **Accepted** 19 December 2016 **Published** 31 January 2017

Citation Santiago-Tirado FH, Onken MD, Cooper JA, Klein RS, Doering TL. 2017. Trojan horse transit contributes to blood-brain barrier crossing of a eukaryotic pathogen. *mBio* 8:e02183-16. <https://doi.org/10.1128/mBio.02183-16>.

Editor Arturo Casadevall, Johns Hopkins Bloomberg School of Public Health

Copyright © 2017 Santiago-Tirado et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Tamara L. Doering, doering@wustl.edu.

free fungi (10–13); and (iii) “Trojan horse” crossing, where fungi traverse the BBB within infected phagocytes (14–17), either transcellularly or paracellularly. However, whether all of these routes are used, the mechanistic details of the routes, and their relative contributions to brain infection are not known.

Evidence that *C. neoformans* uses a Trojan horse mechanism to traverse the BBB is primarily derived from indirect studies *in vivo*, including histological observation of fungi within phagocytes in brain microvasculature and parenchyma (18) and adoptive transfer experiments using infected macrophages (14, 16). In the adoptive transfer studies, intravenous (i.v.) administration of infected macrophages increased brain burden compared to infection with free cryptococci (14, 16). These experiments strongly suggest that phagocyte association provides a dissemination advantage, which could occur either upstream of CNS entry or at the point of BBB traversal. However, interpretation of these studies is complicated by the long intervals between infection and brain harvest, particularly because cryptococci grow both inside and outside host cells and can move between the two compartments while maintaining viability. Interpretation was also complicated in adoptive transfer studies where a heterologous population of macrophages, including free, adherent, and internalized cryptococci, was introduced into mice; *in vivo*, there is no way to track which population of fungi leads to the observed brain burden, so the route of BBB crossing cannot be determined.

Recently, the Trojan horse pathway was examined *in vitro* using a mixture of fungi and monocytes (including free, adherent, and internalized fungi) and a Transwell BBB model. At one day after addition of this mixture, monocytes containing fungi were observed in the lower chamber, suggesting that Trojan horse crossing had occurred (17). As with the earlier *in vivo* experiments, however, the mixed population and the potential for a long incubation to allow multiple cellular interactions (e.g., exit from phagocytes, free fungal crossing, and reuptake in the lower chamber) make it difficult to reach a definitive conclusion about the occurrence of Trojan horse transit in these studies.

Here we combined flow cytometry, fluorescent and live-cell microscopy, and several BBB models to directly demonstrate Trojan horse crossing. We further showed that it occurs via transcellular pore formation, is regulated independently of free fungal entry, and allows mutant fungi that cannot cross alone to invade the brain. Our results conclusively demonstrate the ability of *C. neoformans* to exploit human phagocytes as Trojan horses, contribute significantly to our knowledge of cryptococcal brain entry, and break new ground in the area of BBB transmigration of pathogens.

RESULTS

Isolation of macrophages loaded with single fungi. To rigorously compare the BBB passage of free fungi to that of internalized fungi, we modified a flow cytometry strategy for the isolation of *C. neoformans*-infected phagocytes (19), using *C. neoformans* strain KN99 α and cells of the human monocytic cell line THP-1 (THP). After incubating mCherry-expressing KN99 α (see Materials and Methods) with DFFDA-stained THPs, we applied a sorting strategy (Fig. 1A; see also Fig. S1 in the supplemental material) that additionally used SYTOX red as a host cell viability marker and calcofluor white (CFW) as an impermeant stain to identify externally associated fungi. This allowed us to routinely isolate the desired loaded macrophage population, consisting of healthy host cells, devoid of externally adherent or free fungi (Fig. 1A; box 1), with a count of one yeast per cell on average (Fig. S1A). This population is shown in Fig. 1B (panel 1) and is compared to populations of phagocytes with externally adherent fungi stained by CFW (Fig. 1A; box 2; Fig. 1B, panel 2) and phagocytes with compromised viability stained by SYTOX red (Fig. 1A; box 3; Fig. 1B, panel 3).

BBB transit of free fungi and loaded macrophages. *In vitro* models of the BBB have previously been used to study transit of free cryptococci (20, 21). We generated model BBB (BBB^M) by seeding the human cerebral microvascular endothelial cell line hCMEC/D3 (22, 23) on top of permeable inserts in transwell plates (Fig. 1C). We




FIG 1 Isolation of loaded macrophages and crossing of the BBB by *C. neoformans*. (A) Final phase of the sorting strategy used to isolate phagocytes that were healthy (negative for SYTOX dye) and devoid of external fungi (negative for CFW); the complete strategy is shown in Fig. S1. The boxes corresponding to the gates are labeled as follows: gate 1, healthy phagocytes with only internal fungi; gate 2, healthy phagocytes that have external fungi (with or without internal fungi); gate 3, dead or damaged phagocytes. Results are representative of results of 69 independent analyses. (B) Cells collected from the gates shown in panel A (all shown at the same scale; bar = 10 μ m). Images are representative of results of 4 independent sorting studies where cells were examined microscopically. (C) Diagram of the BBB model used in this study. (D) Transit of free *S. cerevisiae* (*S. cer*) or *C. neoformans* (*C. neo*) in the absence or presence of serum; means and standard deviations (SD) of results are shown for one of two similar studies. (E) Mean and SD values over time for transit (bars, left axis) and TEER (points, right axis), for various starting inocula of opsonized *C. neoformans*. Stars represent TEER values at 0 h. Results from one of two similar studies are shown. (F) Time-dependent transmigration of free fungi, a 1:1 mix of free fungi and empty THPs, and fungus-loaded THPs (1 to 1.49 fungi/host cell). Means and standard errors of the means (SEM) are shown for results of one of seven similar independent experiments. Values plotted for all time course transit assays are cumulative values.

monitored barrier development and integrity by measuring transendothelial electrical resistance (TEER) across the monolayer; once it had stabilized (5 to 6 days), we added particles of interest to the top chamber (representing the blood side of the BBB) and monitored transmigration by assaying samples from the lower chamber (representing the brain side) for CFU. Free *C. neoformans* crossed the BBB^M in a time-dependent manner, consistent with earlier results (20, 21); this was enhanced by the presence of human serum, suggesting that both opsonin-dependent and opsonin-independent mechanisms contribute to this process (Fig. 1D). In contrast, *Saccharomyces cerevisiae*, despite its similar size and shape, showed minimal traversal that was not influenced by serum.

We observed the highest percentage of transmigration in our assays at a fungus/host cell ratio of ~6 (Fig. 1E; 10⁶ fungi), which is the ratio that we used for subsequent studies. Higher levels of inocula did not increase this value, suggesting the presence of a saturable receptor or other limiting host factor. Barrier integrity was maintained over time with all inocula tested, as shown by constant TEER values (Fig. 1E, right axis). This suggests a minor role for paracellular traversal due to BBB^M compromise; instead, free fungi probably cross primarily via a transcellular process (see below).

We next compared the levels of transmigration of free serum-opsonized cryptococci and equal numbers of cryptococci contained within phagocytes; as a control to ensure that the phagocytes alone did not perturb the barrier, we assayed the same number of free fungi mixed 1:1 with uninfected phagocytes immediately prior to assay. Under standard conditions, ~10-fold more opsonized *C. neoformans* fungi crossed free than internalized in macrophages (Fig. 1F) ($P < 0.001$). Interestingly, adding empty macrophages (“*C. neo* + THPs”) inhibited traversal of free fungi ($P = 0.001$). This may reflect competition for free fungi between endothelial cells, characterized by low rates of endocytosis (22), and professional phagocytes (THPs). During the assay, the latter might have engulfed most of the free fungi, preventing them from interacting with endothelial cells to initiate transcellular crossing and yielding a traversal rate similar to that of the loaded macrophages.

Direct visualization of Trojan horses associated with model BBB. Previous studies of Trojan horse crossing have been limited by the use of mixed cell populations and the lack of evidence that fungi were maintained within host phagocytes during actual barrier traversal. Our isolation of loaded macrophages devoid of externally associated cells or free fungi addressed the first concern, and we turned to direct imaging to address the second. We performed 18-h assays with loaded macrophages and imaged both sides of the cell culture inserts (Fig. 2A). Confocal microscopy of the top revealed an endothelial cell layer with abundant associated loaded macrophages (Fig. 2B, top row, and 2C, left). We also observed loaded macrophages associated with the bottom (“brain” side) of the permeable membranes (Fig. 2B, bottom row, and 2C, right). Because free *C. neoformans* fungi do not associate with the cell-free bottom surface of the membrane, the fungi in these macrophages must have crossed the barrier within them, thus directly demonstrating Trojan horse crossing. Movie S1 shows consecutive confocal sections of a field with loaded macrophages on both sides of the membrane.

Physiological influences on BBB^M transit. Cryptococcal meningitis outcome correlates with the levels of immune mediators (24–26). MCP-1 (monocyte chemoattractant protein-1) and *f*MPLP (N-formyl-methionine-leucyl-phenylalanine) are two chemokines that have been specifically studied for their roles in cryptococcal infection (27–30). MCP-1, found at high levels in the brains of cryptococcal meningitis patients (24–26, 31), recruits monocytes to sites of infection and is a critical factor in the immune response against pulmonary cryptococcosis. Formylated peptides such as *f*MPLP are also macrophage activators and are potent chemoattractants for phagocytes; these include neutrophils and dendritic cells, which help control cryptococcal infection (32). Physiological levels of both MCP-1 and *f*MPLP significantly stimulated the transit of loaded macrophages, consistent with their chemoattractant function *in vivo*; neither influenced




FIG 2 Visualization of Trojan horse crossing. (A) Experimental design for visualization of both sides of the permeable membrane. (B) A field of view showing loaded macrophages associated with the endothelial monolayer (top row) and the bottom of the porous membrane with loaded macrophages alone (bottom row). Both mammalian cell types were stained with CellMask plasma membrane dye (blue); THPs were further stained with DFFDA from the flow sorting (green) and contained mCherry-stained fungi (red). Scale bar, 10 μm . (C) Merged images from a larger field of view, again showing all cell types on the top of the membrane (left), whereas only loaded phagocytes are visible on the bottom (right). Scale bar, 20 μm . Images are representative of multiple fields from two independent experiments, each with three independent time points. The fields shown are from a 1-h time point. We observed loaded macrophages associated with the bottom of the membrane most frequently early in the incubation period (more at 1 h than at 2 to 3 h; not shown); this may represent a time-dependent loss of phagocyte viability or ability to initiate transit. See Movie S1 for another example.

the movement of free fungi (Fig. 3A and B). We next tested inositol, which has been shown to promote the transmigration of free *C. neoformans* across a model BBB (33). The presence of inositol at 1 mM, close to the physiological levels in the brain, increased the transit of free fungi but had no effect on the migration of loaded macrophages (Fig. 3C). Importantly, none of these regulatory molecules impaired BBB^M integrity (not shown). Together, these studies showed that Trojan horse and free fungal crossing are independently regulated.

Th1 cytokines, including tumor necrosis factor alpha (TNF- α), are critical for protective immunity and clearance of cryptococcal infection in mice (34). TNF- α and type I interferons (IFNs), such as IFN- β , have been implicated in the control of cryptococcal meningitis in mice and humans (24, 35). These mediators also regulate BBB permeability, especially in response to viral infections (36, 37): TNF- α increases barrier permeability, while IFN- β decreases it. Adding TNF- α or IFN- β to our assays, at levels comparable to those seen in HIV-positive (HIV⁺) patients with cryptococcal meningitis (24–26), yielded small but significant changes in barrier permeability (Fig. 3F and G), consistent with those reports. TNF- α , which increases barrier permeability, also increased the migration of loaded macrophages (Fig. 3D). IFN- β , however, did not affect loaded macrophage migration, possibly because the tightening of the barrier was only transient (Fig. 3G). With free fungi, both TNF- α and IFN- β stimulated transmigration (Fig. 3E), suggesting that these molecules regulate factors beyond barrier permeability that influence free fungal transit.

Trojan horses enable BBB^M transit by fungal mutants that cannot cross alone.

The *CPS1* gene encodes hyaluronic acid (HA) synthase. HA has been implicated in fungal binding to the CD44 surface receptor on hCMECs, which triggers endocytosis and subsequent barrier traversal via a transcellular mechanism (8, 38) (Fig. 4A, left). Consistent with these reports, *cps1* Δ cells had a profound defect in free fungal BBB^M crossing (Fig. 4B, red-shaded bars). When these mutants were passengers inside Trojan




FIG 3 Differential regulation of free and internalized fungal crossing by immune mediators. (A to C) Transmigration of free and internalized fungi in the presence of various chemoattractants, with matched controls. (A) fMLP, N-formyl-methionine-leucyl-phenylalanine peptide (100 nM). DMSO, dimethyl sulfoxide. *, $P < 0.0001$ (by Sidak's multiple-comparison test). (B) MCP-1 (also known as CCL2), monocyte chemoattractant protein-1 (100 ng/ml). *, $P < 0.03$ (by Sidak's multiple-comparison test). (C) INO, inositol (1 mM). *, $P < 0.05$ (by Sidak's multiple-comparison test). (D and E) Transmigration assays using BBB pretreated with TNF- α (10 ng/ml) or IFN- β (1 ng/ml) for 24 h before addition of loaded THPs (*, $P < 0.0003$ [for comparisons between TNF- α and other treatments by Tukey's multiple-comparison test]) (D) or of free fungi (*, $P < 0.0001$ [for comparisons between each compound and PBS by Tukey's multiple-comparison test]) (E). (F and G) TEER values of model BBBs treated with 10 ng/ml TNF- α (F) or 1 ng/ml IFN- β (G) for 24 h prior to initiation of the study ($t = 0$ h), at which point the medium was replaced with fresh medium without cytokines (*, $P < 0.01$; #, $P < 0.0002$ [all compared to PBS at the same time point by Dunnett's multiple-comparison test]).




FIG 4 Loaded macrophages provide an alternative route for mutant cryptococci to gain access into the brain. (A) The roles of Cps1 and Ure1 in BBB crossing. HA (green ovals on the surface of the fungi [red]) made by Cps1 is recognized by the endothelial cell (EC) surface receptor CD44 (blue shapes), which triggers endocytosis of the fungal cells. The accumulation of ammonia generated by Ure1 may damage cellular junction proteins, facilitating fungal brain entry. (B and C) Transmigration of free or internalized fungi, comparing wild-type and either *cps1Δ* (B), or *ure1Δ* (C) mutants. Means plus SEM are plotted. * denotes $P < 0.002$ and $P < 0.0001$ in panels B and C, respectively (both determined by Sidak's multiple-comparison test).

horse macrophages, however, they traversed the BBB^M as efficiently as wild-type fungi (Fig. 4B, blue-shaded bars). The enzyme urease, encoded by *URE1*, is also required for efficient *C. neoformans* brain invasion *in vivo* (11, 12). The mechanism in this case is postulated to be its conversion of urea to ammonia, which could weaken BBB junctions locally and thereby facilitate paracellular crossing (Fig. 4A, right). We indeed observed a defect in free fungal crossing of *ure1Δ* cells (Fig. 4C), although only at late time points, consistent with previous *in vivo* results (39). Notably, TEER values remained stable

throughout this experiment (not shown), indicating that the barrier as a whole maintained integrity; it may be that the time-dependent accumulation of ammonia acts only locally or that the monolayer, if disrupted, is perturbed only transiently and recovers rapidly. Again, the mutation did not inhibit the transmigration of internalized fungi (Fig. 4C), confirming that even mutants that are deficient in free fungal entry into the brain can still exploit the Trojan horse route of transit across the BBB. In both studies, some free fungal crossing still occurred with mutant cells, likely due to the multiple possible mechanisms by which free fungi may traverse the BBB (Fig. 4A).

Trojan horse phagocytes convey cryptococci across transcellular pores. Our confocal microscopy analysis (Fig. 2) provided direct evidence for a Trojan horse mechanism of BBB traversal, in contrast to prior indirect evidence for such transit of a variety of pathogens (40–45). To observe cryptococcal transit over time and to obtain mechanistic insights, we used live-cell microscopy. We first seeded hCMECs on collagen-coated polyacrylamide (PA) hydrogels, which reproduce the physical properties of *in vivo* tissues (46), and monitored the monolayers by phase-contrast microscopy to confirm formation of a single, uninterrupted layer with uniform junctions (Fig. 5A); transmission electron microscopy (TEM) also showed a thin cell monolayer with minimal cytosolic overlap and well-developed junctions (Fig. S2A). To observe intercellular interactions, we then added primary human monocytes loaded with *C. neoformans* (see Materials and Methods) and acquired images every minute for 6 to 16 h. These cells interacted with the endothelial layer more actively than loaded THP-1 cells, with 36% of 60 total events recorded showing Trojan horse transmigration. The typical pattern of Trojan horse crossing that we observed is shown in Fig. 5B and C (images extracted from Movies S2 and S3, respectively). The first image (panel 1) in each sequence shows a loaded monocyte associated with the endothelial cell layer. Host membranes then extend around the loaded phagocyte (panel 2, arrows), a process that follows extensive membrane activity at that site (see Movies S2 and S3) and leads to formation of a transcellular pore (47) (panel 3). After transmigration of the Trojan horse through the pore and pore closure, the fungi can still be seen through the endothelial cell (panel 4), but with a marked loss of refractility compared to the early images. These fungi remained within the original phagocytic cell throughout the process (better visualized in the single-color channels of the movies).

To observe transmigration events at higher resolution, we prepared samples as described for the video microscopy, incubated the samples for 6 h, washed the samples extensively to remove nonassociated loaded monocytes and media components, and fixed the samples for transmission electron microscopy (TEM). Consistent with the lengthy association between phagocytes and endothelial cells that precedes the rapid progression of transmigration shown in our videos, our TEM images included numerous examples of loaded phagocytes interacting with the endothelial cell monolayer (Fig. S2B) and only occasional instances of transmigration events in progress. One of the latter (Fig. 5D) demonstrates the partial progress of a monocyte, which carries a budding cryptococcal cell, through a transcellular pore. TEM also showed free cryptococcal cells within brain endothelial cells, presumably in the process of transcytosis (Fig. S2C).

We performed similar live-cell studies of loaded THPs and observed various known behaviors of intracellular *C. neoformans*, including intracellular proliferation (not shown), lytic exocytosis (Movie S4, left side), and nonlytic exocytosis (Movie S4, right side) (48). We also observed several instances of cell-to-cell transmission of fungal cells, which has been reported to occur between macrophages (49, 50). In our studies, the fungal movement was from phagocytic to endothelial cells (Movie S5), a novel finding. Free fungi in our movies, probably arising from lytic or nonlytic exit from the loaded macrophages, sometimes associated with or were internalized by endothelial cells, in one case subsequently replicating and then being expelled (Movie S6).

In 10% of the traversal events that we observed, the fungal cargo appeared to impede monocyte transit across the endothelial cell layer, with the portion of the host




FIG 5 Visualization of Trojan horse crossing by real-time and electron microscopy. (A) hCMEC monolayers were grown on glass or 0.4% PA pads were grown to confluence and fixed, and adherens junctions were stained with anti-VE-cadherin antibody. Nuclei were stained with propidium iodide. (B and C) Two examples of loaded primary human monocytes crossing endothelia, from Movie S2 (B) and Movie S3 (C); see text for details. (D) TEM of a loaded monocyte in the process of transendothelial migration (left), with a corresponding drawing to identify structures (right). N, nucleus; V, vacuole; F, fungal cell; B, brain endothelial cell.

cell containing the fungi apparently stuck on the luminal side for the duration of the movie (Movie S7, red arrow). To assess the potential interference with monocyte transit and possible specificity of this process, we compared the transit of empty THPs to that of THPs loaded with either *C. neoformans* or *S. cerevisiae* (Fig. S3A). These studies, whose results we analyzed by both measuring fluorescence (Fig. S3B) and directly imaging and counting cells in the lower chamber (Fig. S3C), suggested that the presence of either yeast slightly inhibited host cell transmigration; there was no difference between the two fungal species in this regard.

DISCUSSION

Because *C. neoformans* thrives intracellularly, the idea of the use of a Trojan horse model for its dissemination to the CNS has been historically appealing and is supported

by a variety of indirect studies. However, confirming Trojan horse transit has posed significant experimental challenges, despite its importance for understanding how *C. neoformans* and related species colonize the brain (17, 51, 52). Here we show for the first time that cryptococcal cells maintained within phagocytes cross brain microendothelial barriers, directly demonstrating Trojan horse transit.

Our comparisons of the transit of free fungi to that of phagocytes with internalized yeast showed that free fungi crossed our model BBB more efficiently. However, these *in vitro* studies likely underestimate the role of Trojan horse transit *in vivo* for several reasons. First, free *C. neoformans* does not survive well in serum and is rapidly cleared from the bloodstream following i.v. inoculation in mice (53, 54). Second, unlike free cryptococci, phagocytic cells stick, albeit transiently, to the bottom of the membrane as they cross a model BBB. Although this allowed us to directly demonstrate the transit of loaded macrophages, it likely leads to an underestimation of the internal fungi when the medium in the lower chamber is sampled, as in our assays. In addition, we found that host signals relevant to infection differentially regulate the crossings of free and internalized fungi; these factors may cause greater levels of Trojan horse crossing during infection *in vivo* than we detected *in vitro*. Finally, it has been suggested that free fungi adherent to the luminal side of brain microvasculature may be removed by neutrophils (55), a process that would reduce their transit but would not occur in our system.

The balance of routes used by *C. neoformans* to enter the brain may change during the course of infection. This could be mediated in part by changing levels of host immune regulators, which modulate BBB crossing. These regulators may be influenced by characteristics of the infecting strain of *C. neoformans*, such as the release of the polysaccharide capsule, a major virulence factor. For example, the level of MCP-1, which we found specifically stimulated Trojan horse crossing, is decreased in infections with strains shedding small amounts of capsule compared to strains shedding intermediate levels. Similarly, high levels of TNF- α , which stimulated both Trojan horse and free fungus traversal, correlate with infecting strains that have high levels of capsule shedding (4). The balance of routes could also be influenced by the progression of the disease itself. In our work, the greatest specific effect on Trojan horse traversal was caused by *f*MPLP. Formyl peptides such as *f*MPLP stimulate not only leukocyte chemotaxis but also degranulation, superoxide production, and activation of integrins for cell adhesion, all of which promote inflammation. Both *in vivo* and *in vitro* studies have suggested that endothelial damage occurs late in cryptococcal infection (13, 54). Such damage would result in release of formyl peptides, again potentially shifting the balance of CNS entry routes.

Our live-cell microscopy of Trojan horse crossing showed a distinctive sequence of events (Fig. 5). These events are consistent with the process of transendothelial pore formation, cartooned in Fig. 6, where the phagocyte (green) essentially crosses through a “donut hole” that forms in the endothelial cell, without ever entering its cytosol. This mechanism has not been considered in the cryptococcal literature, although it is consistent with models for inflammatory cell crossing in the brain. Due to the presence of extremely tight junctions in brain endothelia, transendothelial pore transit accounts for up to 90% of cellular crossing of the BBB, in contrast to other endothelia, where most crossing occurs paracellularly (56). A minor role for paracellular transit is consistent with the stable TEER values measured during our assays. It is also consistent with our observations revealing that, in several videos where cell boundaries are clear, crossing occurred at the cell body rather than at the edges (Movies S2 and S3 and data not shown). While it is conceivable that a particle could cross the endothelial barrier without perturbing TEER (if the apical junction sealed before the basal one was breached), we consider this unlikely because of the kinetics of crossing and the large size of the fungus relative to the thickness of the endothelial layer (Fig. S2C).

We also recorded other behaviors that could contribute to *C. neoformans* BBB crossing. These included nonlytic escape from phagocytes and a novel process of fungal movement from phagocytes directly into endothelial cells; both of these suggest




FIG 6 Mechanisms of brain infection by *C. neoformans*. (A) Depicted are wild-type fungi (red ovals) crossing the BBB either free (1) or within Trojan horse phagocytes (2). Mutant fungi (orange ovals) cannot cross alone (3) but can use Trojan horse transit as an alternative route. See text for details on transendothelial pore formation for Trojan horse transit. (B) Loaded phagocytes potentially contribute to brain invasion by pathways that do not involve true Trojan horse transit (2). Phagocytes can bring the fungus to the CNS internally and then exit the phagocyte by nonlytic exocytosis and cross the BBB as free yeast by transcytosis (1). Finally, we observed two instances of direct cell-to-cell transfer of fungal cells from phagocytes to endothelial cells (3), supporting the hypothesis of a “taxi” mechanism, where loaded phagocytes deliver fungal cells directly into brain endothelial cells. Pink, blood vessel lumen; pale green, brain parenchyma; blue cells, brain endothelial cells; green cells, infected phagocytes; shaded gray rectangle, the extracellular matrix that forms the BBB basal membrane.

additional modes of BBB traversal where phagocytes participate without acting as Trojan horses. For example, phagocytes could bring cryptococci to the BBB, where they would either exit and cross transcellularly on their own or be delivered directly into the endothelia by cell-to-cell transfer (Fig. 6B and Movies S4 and S5). Although Trojan horse crossing was more frequent (36% of recorded events) than nonlytic exocytosis or direct transfer (26% or 3%, respectively) in our system, the latter mechanisms may contribute to brain entry *in vivo* (19, 57).

The presence of internalized fungi, whether *C. neoformans* or model yeast, had a modest inhibitory effect on phagocyte traversal (Fig. S3). Our movies suggest that this may be because they contain relatively large and rigid structures that are not easily accommodated by the endothelial pore; this idea is also supported by a correlation between this inhibition and the number of internalized fungi per cell (not shown). The effect of the physical parameters of the yeast is also evident in our TEM observations of free fungal transit. The thin brain endothelium is dramatically distorted by fungal entry, such that the yeast contacts both cell surfaces (Fig. S2C). The long fibers surrounding the internalized cryptococci are presumably cytoskeletal elements, which

could potentially trigger expulsive events toward either side, such as those shown in Movie S6, where the fungal cell is internalized by and subsequently exits from the same face of the endothelial layer.

We found that fungal cells that cannot cross the BBB on their own (Fig. 6, orange ovals) can still reach the brain inside phagocytes, at levels comparable to those seen with normal fungi. This is likely to be relevant to pathogenesis, as exemplified by mutants lacking *Cps1*, which produces a ligand for endothelial cell CD44 (Fig. 4A). Although independent transmigration of these mutant fungi is reduced ~50% compared to that of wild-type fungi *in vitro*, wild-type infections of CD44^{-/-} mice show a smaller reduction in brain burden and a minimal effect on virulence (58). This can be explained by a model where most circulating fungal cells are inside phagocytes. These fungi would not need the CD44 interaction to efficiently cross the BBB, consistent with the *in vivo* observations and supporting the idea of a role for Trojan horse crossing *in vivo*. These findings highlight the need to consider internalized fungi in assessments of antifungal agents and the potential value of identifying compounds that inhibit intracellular replication of cryptococci, as in a recent screen (59).

Any intracellular pathogen that can survive within phagocytes can potentially exploit them as Trojan horses for dissemination or delivery into target organs, although some may use other mechanisms, as suggested recently for *Toxoplasma gondii* (60). Our work shows the importance of dissecting these mechanisms for *C. neoformans* and other neuropathogens and provides methods and approaches for doing so.

MATERIALS AND METHODS

Mammalian cells and growth conditions. The human monocytic cell line THP-1 (TIB-202, from the ATCC) was cultured and differentiated as described in reference 61. These cells were negative for mycoplasma. For the model BBB, we obtained the immortalized human brain endothelial cell line hCMEC/D3, described and reviewed in reference 22. These cells were obtained from Babette Weksler (Cornell University Medical College) and were grown as described in reference 23. Primary blood monocytes were isolated by negative immunoselection (Pan Monocyte isolation kit; Miltenyi Biotec, Inc.) from peripheral blood mononuclear cells (PBMCs) that were obtained from leukoreduction (LRS) chambers following routine platelet donations at the apheresis center at Washington University School of Medicine. The cells were kept in suspension by growth in ultra-low-adherence flasks (Corning) in human peripheral blood monocyte (hPBM) medium (RPMI medium with L-glutamine and sodium bicarbonate, 10% fetal bovine serum [FBS], 1 mM sodium pyruvate, 1× penicillin-streptomycin [PenStrep], 1% nonessential amino acids [NEAA], and 10 mM HEPES [pH 7]).

Fungal strains. Most studies used *C. neoformans* strain KN99 α (62), provided by Joe Heitman, or mCherry-expressing KN99 α from Jennifer Lodge and Raj Upadhyay. A *ure1 Δ* strain in the KN99 α background was from the 2015 Madhani partial-deletion collection (Fungal Genetics Stock Center, University of Missouri—Kansas City, Kansas City, MO). A *cps1 Δ* strain in the H99 α background was obtained from an earlier Madhani collection (63); H99 α was used as a control for experiments performed with this mutant. *S. cerevisiae* strain BY4741 (64), provided by Michael Brent, was transformed with an integrative plasmid expressing cytoplasmic mCherry (from Addgene).

Fungal uptake by phagocytes. THPs seeded at 1.67×10^5 cells/ml and grown in T175 flasks were labeled with 1 μ M DFFDA succinimidyl ester (DFFDA-SE) (CellTrace Oregon Green; Thermo Fisher Scientific) and challenged with mCherry-expressing fungi or fungi stained with 15 μ M DDAO-SE (CellTrace Far Red; Thermo Fisher Scientific) at a multiplicity of infection (MOI) of 3. A 2.5-h incubation at this MOI yielded close to 1 yeast per host cell (Fig. S1A), with more than half of the THPs infected and relatively few externally adherent fungi (Fig. S1B). For some uptake studies, fungi were opsonized (30 min at 37°C with rotation) with 40% fresh serum (from healthy individuals at the Washington University School of Medicine; Institutional Review Board [IRB] 201101914) before being exposed to phagocytes. After 2.5 h, flasks were washed twice with 2 mM EDTA-phosphate-buffered saline (PBS) to remove free and loosely adherent fungi and the THPs were detached with CellStripper (Corning), a nonenzymatic cell dissociation solution. The cells were then washed once with medium lacking phenol red and resuspended in Presort buffer (BD Biosciences) with 10 μ g/ml calcofluor white (CFW) to stain external fungi and 5 nM SYTOX red (using mCherry-expressing fungi) or SYTOX orange (using DDAO-stained fungi) as a host cell viability dye. A similar approach was used with primary blood monocytes (not shown), except that initial washes were done by centrifugation and uptake was performed in medium without phenol red at an MOI of 1 for at least 3 h; infected cells were then sedimented and resuspended in Presort buffer containing CFW and SYTOX red as described above.

Flow cytometry. To optimize phagocytosis assays, we analyzed uptake reactions on an LSRII instrument (BD Biosciences). Cell sorting was performed on a FACSAria II system (BD Biosciences) following standard procedures with appropriate precautions for a biosafety level 2-plus (BSL-2+) organism. The gating strategy is shown in Fig. S1C to F (and the last step only is shown in Fig. 1A); at least 10^6 cells were routinely collected from gate 1 in Fig. 1A and Fig. S1F. All results were analyzed and formatted for presentation using FlowJo software (Treestar).

In vitro BBB. BBB^M (Fig. 1C) examples were generated as described in reference 23 with some modifications. Briefly, hCMEC/D3 were seeded at 5×10^4 cells/cm² (for 0.9-cm² permeable inserts) or 6×10^4 cells/cm² (for 0.33-cm² inserts) on the apical side of 8- μ m-porosity inserts (BD Falcon, Corning) that had been coated with 150 μ g/ml Cultrex rat collagen I (R&D Systems) for at least 1 h at 37°C prior to washing with PBS and adding the cells. The cells were grown for 4 to 5 days in EBM2 (Lonza) supplemented with FBS (5%), penicillin-streptomycin (1%), hydrocortisone (1.4 μ M), ascorbic acid (5 μ g/ml), chemically defined lipid concentrate (1%), HEPES (10 mM), basic fibroblast growth factor (bFGF) (1 ng/ml), and human vascular endothelial growth factor (hVEGF) (2 ng/ml). At 24 h prior to the assays (when the monolayer was already confluent), the medium was replaced with differentiation medium (as described above but with 1% FBS and no growth factors). TEER was measured with an EVOM2 (WPI) with either an STX2 electrode (for 12-well plates) or an STX100 electrode (for 24-well plates). We routinely achieved values of $\sim 80 \Omega \cdot \text{cm}^2$ for 0.9-cm² inserts and $\sim 60 \Omega \cdot \text{cm}^2$ for 0.33-cm² inserts with 8- μ m-pore-size membranes. We observed much lower TEER values when we used inserts with 0.4- μ m pores (not shown). These results were similar to what was found in a recent study, although even those barriers were reported to still maintain integrity with respect to large molecules (65).

Transendothelial migration assays. For studies with free fungi, log-phase *C. neoformans* fungi were washed twice in PBS and 10^8 cells were resuspended and incubated in 40% fresh human serum–PBS for 30 min at 37°C. The cells were collected by centrifugation and resuspended at 2×10^6 cells/ml in migration media (RPMI medium containing 1% FBS), and 500 μ l of the suspension was added to the top of a permeable insert (usually 0.9-cm² permeable inserts in 12-well plates), which was then moved into a new plate with 1.5 ml of migration medium/well. At each time point, TEER was measured. Inserts were then moved to new plates with prewarmed migration medium, and aliquots of the prior lower chamber were spotted on yeast extract-peptone-dextrose (YPD) plates for CFU quantification. For studies involving loaded macrophages, 10^5 particles (free fungi, loaded macrophages, or a 1:1 mix of free fungi and empty macrophages)–300 μ l of migration media was added to the top of a 0.33-cm² Corning HTS insert (in a fixed-format 24-well plate to allow plate centrifugation without cross-contamination). Prior to each sampling, the plate was subjected to centrifugation (1,000 rpm, 5 min, 37°C) and the insert assembly was moved to a new plate containing 1 ml migration medium/well; aliquots from the prior wells were spotted on YPD plates for CFU quantification. In some studies, chemoattractants or cytokines were present in the bottom chamber of each well at the concentrations noted in the text. Excluding Fig. 1, all experiments incorporated 4 technical replicates for each condition tested. This allowed experiments to be performed in individual multiwell plates, eliminating plate-to-plate variation for this complex system. Each experiment was performed at least twice independently, with similar results; one example is shown. Details of replicates prepared as described for Fig. 1 are provided in the corresponding legend.

Direct visualization of insert membranes. BBB transit assays were performed as described above, the inserts were removed from 12-well plates and immersed twice in HBSS+ (Hanks balanced salt solution containing 1% glutamine, 1% PenStrep, 140 mg/liter CaCl₂, 100 mg/liter MgCl₂, 100 mg/liter MgSO₄, and without phenol red), after which both sides were fixed with 4% formaldehyde–PBS (10 min, room temperature [RT]). The fixed inserts were washed in HBSS+ twice and both sides stained with CellMask Deep Red Plasma membrane stain (Thermo Fisher Scientific) (1:10,000 in PBS; 10 min, RT) and washed twice in HBSS+. The inserts were then excised from the plastic housing using 10-mm-diameter skin biopsy specimen punches and placed monolayer side up on a bubble of mounting media on a microscope slide. Another few microliters of mounting media and a coverslip were then applied. After the mounting media had cured, the membrane was viewed on a Zeiss LSM 510 confocal laser scanning system. To image cells directly, we used Fluoroblok plates and media without phenol red. Wells were washed once with HBSS+ and fixed as described above, and the lower part of the insert was imaged without removal from the plate using a Cytation3 cell imaging multimode plate reader (Bio-Tek Instruments, Inc.).

Soft substrate preparation and microscopy. PA pads were prepared in 35-mm-diameter glass-bottomed dishes as previously described (66), coated with 50 μ g/ml rat collagen, and used as the substrates for hCMEC monolayers that reproduce the physical properties of *in vivo* tissues (46). For staining of junctions, monolayers were washed with HBSS+ and fixed either with 100% cold methanol (for staining with anti-vascular endothelial cadherin [anti-VE-cadherin] [clone 55-7H1; BD Biosciences]) or with 4% formaldehyde–HBSS+ (for staining with ZO-1 [clone 1A12; Invitrogen] or with claudin-5 [clone 4C3C2; Invitrogen]; not shown). The dishes were then either incubated for 6 h, washed, and processed for TEM or placed into an environmental chamber (Stage Top incubator; Tokai Hit, Shizuokaken, Japan) at 37°C and 5% CO₂ on an inverted microscope (Olympus IX72) for video recording, with images (DIC [differential interference contrast], fluorescein isothiocyanate [FITC], and Texas Red channels) captured every minute for 6 to 16 h.

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at <https://doi.org/10.1128/mBio.02183-16>.

FIG S1, TIF file, 1.2 MB.

FIG S2, TIF file, 4.9 MB.

FIG S3, TIF file, 1.3 MB.

MOVIE S1, MOV file, 5 MB.

MOVIE S2, MOV file, 13.2 MB.

MOVIE S3, MOV file, 8.5 MB.

MOVIE S4, MOV file, 11.5 MB.

MOVIE S5, MOV file, 6.3 MB.

MOVIE S6, MOV file, 9.5 MB.

MOVIE S7, MOV file, 8.7 MB.

ACKNOWLEDGMENTS

We thank the Doering group for comments and helpful discussions; Joe Heitman for KN99 α ; Jennifer Lodge for mCherry-KN99 α ; Wandy Beatty of the Molecular Microbiology Imaging Center for advice on microscopy; Robyn Roth in the Washington University Center for Cellular Imaging (WUCCI) for TEM; and Todd Fehniger for platelet-depleted PBMCs.

This work was supported by NIH grants GM118171 and GM38542 to J.A.C.; NIH AI114549 to T.L.D. and R.S.K.; and NIH AI078795, AI102882, and a BJH Foundation Clinical Investigator Award through the WUCCI to T.L.D. Support to F.H.S.-T. included NIH T32 grant AI007172 and a Postdoctoral Enrichment Program Award from the Burroughs Wellcome Fund.

F.H.S.-T. and T.L.D. designed the experiments with advice from R.S.K. and J.A.C. F.H.S.-T. performed all experiments. M.D.O. provided training and guidance for live-cell microscopy. F.H.S.-T. and T.L.D. wrote the manuscript, and all authors contributed to editing.

REFERENCES

- Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. 2012. Hidden killers: human fungal infections. *Sci Transl Med* 4:165rv13. <https://doi.org/10.1126/scitranslmed.3004404>.
- Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. 2009. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. *AIDS* 23:525–530. <https://doi.org/10.1097/QAD.0b013e3283222fac>.
- Fox DS, Djordjevic JT, Sorrell TC. 2011. Signaling cascades and enzymes as cryptococcus virulence factors, p 217–234. In Heitman J, Kozel TR, Kwon-Chung KJ, Perfect J, Casadevall A (ed), *Cryptococcus: from human pathogen to model yeast*. ASM Press, Washington, DC.
- Srikanta D, Santiago-Tirado FH, Doering TL. 2014. *Cryptococcus neoformans*: historical curiosity to modern pathogen. *Yeast* 31:47–60. <https://doi.org/10.1002/yea.2997>.
- Serlin Y, Shelef I, Knyazer B, Friedman A. 2015. Anatomy and physiology of the blood-brain barrier. *Semin Cell Dev Biol* 38:2–6. <https://doi.org/10.1016/j.semcdb.2015.01.002>.
- Chang YC, Stins MF, McCaffery MJ, Miller GF, Pare DR, Dam T, Paul-Satyaseela M, Kim KS, Kwon-Chung KJ, Paul-Satyasee M. 2004. Cryptococcal yeast cells invade the central nervous system via transcellular penetration of the blood-brain barrier. *Infect Immun* 72:4985–4995. <https://doi.org/10.1128/IAI.72.9.4985-4995.2004>.
- Huang SH, Long M, Wu CH, Kwon-Chung KJ, Chang YC, Chi F, Lee S, Jong A. 2011. Invasion of *Cryptococcus neoformans* into human brain microvascular endothelial cells is mediated through the lipid rafts-endocytic pathway via the dual specificity tyrosine phosphorylation-regulated kinase 3 (DYRK3). *J Biol Chem* 286:34761–34769. <https://doi.org/10.1074/jbc.M111.219378>.
- Jong A, Wu CH, Shackelford GM, Kwon-Chung KJ, Chang YC, Chen HM, Ouyang Y, Huang SH. 2008. Involvement of human CD44 during *Cryptococcus neoformans* infection of brain microvascular endothelial cells. *Cell Microbiol* 10:1313–1326. <https://doi.org/10.1111/j.1462-5822.2008.01128.x>.
- Maruvada R, Zhu L, Pearce D, Zheng Y, Perfect J, Kwon-Chung KJ, Kim KS. 2012. *Cryptococcus neoformans* phospholipase B1 activates host cell Rac1 for traversal across the blood-brain barrier. *Cell Microbiol* 14:1544–1553. <https://doi.org/10.1111/j.1462-5822.2012.01819.x>.
- Chen SH, Stins MF, Huang SH, Chen YH, Kwon-Chung KJ, Chang Y, Kim KS, Suzuki K, Jong AY. 2003. *Cryptococcus neoformans* induces alterations in the cytoskeleton of human brain microvascular endothelial cells. *J Med Microbiol* 52:961–970. <https://doi.org/10.1099/jmm.0.05230-0>.
- Olszewski MA, Noverr MC, Chen GH, Toews GB, Cox GM, Perfect JR, Huffnagle GB. 2004. Urease expression by *Cryptococcus neoformans* promotes microvascular sequestration, thereby enhancing central nervous system invasion. *Am J Pathol* 164:1761–1771. [https://doi.org/10.1016/S0002-9440\(10\)63734-0](https://doi.org/10.1016/S0002-9440(10)63734-0).
- Shi M, Li SS, Zheng C, Jones GJ, Kim KS, Zhou H, Kubes P, Mody CH. 2010. Real-time imaging of trapping and urease-dependent transmigration of *Cryptococcus neoformans* in mouse brain. *J Clin Invest* 120:1683–1693. <https://doi.org/10.1172/JCI41963>.
- Vu K, Eigenheer RA, Phinney BS, Gelli A. 2013. *Cryptococcus neoformans* promotes its transmigration into the central nervous system by inducing molecular and cellular changes in brain endothelial cells. *Infect Immun* 81:3139–3147. <https://doi.org/10.1128/IAI.00554-13>.
- Charlier C, Nielsen K, Daou S, Brigitte M, Chretien F, Dromer F. 2009. Evidence of a role for monocytes in dissemination and brain invasion by *Cryptococcus neoformans*. *Infect Immun* 77:120–127. <https://doi.org/10.1128/IAI.01065-08>.
- Kechichian TB, Shea J, Del Poeta M. 2007. Depletion of alveolar macrophages decreases the dissemination of a glucosylceramide-deficient mutant of *Cryptococcus neoformans* in immunodeficient mice. *Infect Immun* 75:4792–4798. <https://doi.org/10.1128/IAI.00587-07>.
- Santangelo R, Zoellner H, Sorrell T, Wilson C, Donald C, Djordjevic J, Shounan Y, Wright L. 2004. Role of extracellular phospholipases and mononuclear phagocytes in dissemination of cryptococcosis in a murine model. *Infect Immun* 72:2229–2239. <https://doi.org/10.1128/IAI.72.4.2229-2239.2004>.
- Sorrell TC, Juillard PG, Djordjevic JT, Kaufman-Francis K, Dietmann A, Milonig A, Combes V, Grau GE. 2016. Cryptococcal transmigration across a model brain blood-barrier: evidence of the Trojan horse mechanism and differences between *Cryptococcus neoformans* var. *grubii* strain H99 and *Cryptococcus gattii* strain R265. *Microbes Infect* 18:57–67. <https://doi.org/10.1016/j.micinf.2015.08.017>.
- Chrétien F, Lortholary O, Kansau I, Neuville S, Gray F, Dromer F. 2002. Pathogenesis of cerebral *Cryptococcus neoformans* infection after fungemia. *J Infect Dis* 186:522–530. <https://doi.org/10.1086/341564>.
- Nicola AM, Robertson EJ, Albuquerque P, Derengowski Lda S, Casadevall A. 2011. Nonlytic exocytosis of *Cryptococcus neoformans* from macrophages occurs in vivo and is influenced by phagosomal pH. *mBio* 2:e00167-11. <https://doi.org/10.1128/mBio.00167-11>.
- Sabiiti W, May RC. 2012. Capsule independent uptake of the fungal pathogen *Cryptococcus neoformans* into brain microvascular endothelial cells. *PLoS One* 7:e35455. <https://doi.org/10.1371/journal.pone.0035455>.
- Vu K, Weksler B, Romero I, Couraud PO, Gelli A. 2009. Immortalized

- human brain endothelial cell line HCMEC/D3 as a model of the blood-brain barrier facilitates in vitro studies of central nervous system infection by *Cryptococcus neoformans*. *Eukaryot Cell* 8:1803–1807. <https://doi.org/10.1128/EC.00240-09>.
22. Weksler B, Romero IA, Couraud PO. 2013. The hCMEC/D3 cell line as a model of the human blood brain barrier. *Fluids Barriers CNS* 10:16. <https://doi.org/10.1186/2045-8118-10-16>.
 23. Daniels BP, Cruz-Orengo L, Pasioka TJ, Couraud PO, Romero IA, Weksler B, Cooper JA, Doering TL, Klein RS. 2013. Immortalized human cerebral microvascular endothelial cells maintain the properties of primary cells in an in vitro model of immune migration across the blood brain barrier. *J Neurosci Methods* 212:173–179. <https://doi.org/10.1016/j.jneumeth.2012.10.001>.
 24. Mora DJ, Fortunato LR, Andrade-Silva LE, Ferreira-Paim K, Rocha IH, Vasconcelos RR, Silva-Teixeira DN, Nascentes GA, Silva-Vergara ML. 2015. Cytokine profiles at admission can be related to outcome in AIDS patients with cryptococcal meningitis. *PLoS One* 10:e0120297. <https://doi.org/10.1371/journal.pone.0120297>.
 25. Panackal AA, Wuest SC, Lin YC, Wu T, Zhang N, Kosa P, Komori M, Blake A, Browne SK, Rosen LB, Hagen F, Meis J, Levitz SM, Quezado M, Hammond D, Bennett JE, Bielekova B, Williamson PR. 2015. Paradoxical immune responses in non-HIV cryptococcal meningitis. *PLoS Pathog* 11:e1004884. <https://doi.org/10.1371/journal.ppat.1004884>.
 26. Boulware DR, von Hohenberg M, Rolfes MA, Bahr NC, Rhein J, Akampurira A, Williams DA, Taseera K, Schutz C, McDonald T, Muzoora C, Meintjes G, Meya DB, Nielsen K, Huppler Hullsiek K. 2016. Human immune response varies by the degree of relative cryptococcal antigen shedding. *Open Forum Infect Dis* 3:ofv194. <https://doi.org/10.1093/ofid/ofv194>.
 27. He W, Casadevall A, Lee SC, Goldman DL. 2003. Phagocytic activity and monocyte chemotactic protein expression by pulmonary macrophages in persistent pulmonary cryptococcosis. *Infect Immun* 71:930–936. <https://doi.org/10.1128/IAI.71.2.930-936.2003>.
 28. Kawakami K, Kinjo Y, Uezu K, Yara S, Miyagi K, Koguchi Y, Nakayama T, Taniguchi M, Saito A. 2001. Monocyte chemoattractant protein-1-dependent increase of V alpha 14 NKT cells in lungs and their roles in Th1 response and host defense in jiptococcal infection. *J Immunol* 167:6525–6532. <https://doi.org/10.4049/jimmunol.167.11.6525>.
 29. Kozel TR, Pfrommer GS, Redelman D. 1987. Activated neutrophils exhibit enhanced phagocytosis of *Cryptococcus neoformans* opsonized with normal human serum. *Clin Exp Immunol* 70:238–246.
 30. Dong ZM, Murphy JW. 1997. Cryptococcal polysaccharides bind to CD18 on human neutrophils. *Infect Immun* 65:557–563.
 31. Guillot L, Carroll SF, Homer R, Qureshi ST. 2008. Enhanced innate immune responsiveness to pulmonary *Cryptococcus neoformans* infection is associated with resistance to progressive infection. *Infect Immun* 76:4745–4756. <https://doi.org/10.1128/IAI.00341-08>.
 32. Leopold Wager CM, Hole CR, Wozniak KL, Wormley FL, Jr. 2016. *Cryptococcus* and phagocytes: complex interactions that influence disease outcome. *Front Microbiol* 7:105. <https://doi.org/10.3389/fmicb.2016.00105>.
 33. Liu TB, Kim JC, Wang Y, Toffaletti DL, Eugenin E, Perfect JR, Kim KJ, Xue C. 2013. Brain inositol is a novel stimulator for promoting *Cryptococcus* penetration of the blood-brain barrier. *PLoS Pathog* 9:e1003247. <https://doi.org/10.1371/journal.ppat.1003247>.
 34. Wozniak KL, Ravi S, Macias S, Young ML, Olszewski MA, Steele C, Wormley FL. 2009. Insights into the mechanisms of protective immunity against *Cryptococcus neoformans* infection using a mouse model of pulmonary cryptococcosis. *PLoS One* 4:e6854. <https://doi.org/10.1371/journal.pone.0006854>.
 35. Sionov E, Mayer-Barber KD, Chang YC, Kauffman KD, Eckhaus MA, Salazar AM, Barber DL, Kwon-Chung KJ. 2015. Type I IFN induction via poly-ICLC protects mice against cryptococcosis. *PLoS Pathog* 11:e1005040. <https://doi.org/10.1371/journal.ppat.1005040>.
 36. Daniels BP, Klein RS. 2015. Knocking on closed doors: host interferons dynamically regulate blood-brain barrier function during viral infections of the central nervous system. *PLoS Pathog* 11:e1005096. <https://doi.org/10.1371/journal.ppat.1005096>.
 37. Rochford KD, Cummins PM. 2015. The blood-brain barrier endothelium: a target for pro-inflammatory cytokines. *Biochem Soc Trans* 43:702–706. <https://doi.org/10.1042/BST20140319>.
 38. Chang YC, Jong A, Huang S, Zerfas P, Kwon-Chung KJ. 2006. *CPS1*, a homolog of the *Streptococcus pneumoniae* type 3 polysaccharide synthase gene, is important for the pathobiology of *Cryptococcus neoformans*. *Infect Immun* 74:3930–3938. <https://doi.org/10.1128/IAI.00089-06>.
 39. Singh A, Panting RJ, Varma A, Saijo T, Waldron KJ, Jong A, Ngamskulrungrroj P, Chang YC, Rutherford JC, Kwon-Chung KJ. 2013. Factors required for activation of urease as a virulence determinant in *Cryptococcus neoformans*. *mBio* 4:e00220-13. <https://doi.org/10.1128/mBio.00220-13>.
 40. Join-Lambert OF, Ezine S, Le Monnier A, Jaubert F, Okabe M, Berche P, Kayal S. 2005. *Listeria monocytogenes*-infected bone marrow myeloid cells promote bacterial invasion of the central nervous system. *Cell Microbiol* 7:167–180. <https://doi.org/10.1111/j.1462-5822.2004.00444.x>.
 41. Lachenmaier SM, Deli MA, Meissner M, Liesenfeld O. 2011. Intracellular transport of *Toxoplasma gondii* through the blood-brain barrier. *J Neuroimmunol* 232:119–130. <https://doi.org/10.1016/j.jneuroim.2010.10.029>.
 42. Neal JW. 2014. Flaviviruses are neurotropic, but how do they invade the CNS? *J Infect* 69:203–215. <https://doi.org/10.1016/j.jinf.2014.05.010>.
 43. Nguyen L, Pieters J. 2005. The Trojan horse: survival tactics of pathogenic mycobacteria in macrophages. *Trends Cell Biol* 15:269–276. <https://doi.org/10.1016/j.tcb.2005.03.009>.
 44. Zlotkin A, Chilmonczyk S, Eyngor M, Hurvitz A, Ghittino C, Eldar A. 2003. Trojan horse effect: phagocyte-mediated *Streptococcus iniae* infection of fish. *Infect Immun* 71:2318–2325. <https://doi.org/10.1128/IAI.71.5.2318-2325.2003>.
 45. O'Neill AM, Thurston TL, Holden DW. 2016. Cytosolic replication of group A streptococcus in human macrophages. *mBio* 7:e00020-16. <https://doi.org/10.1128/mBio.00020-16>.
 46. Tse JR, Engler AJ. 2010. Preparation of hydrogel substrates with tunable mechanical properties. *Curr Protoc Cell Biol* 47:10.16:10.16.1–10.16.16. <https://doi.org/10.1002/0471143030.cb1016s47>.
 47. Muller WA. 2015. The regulation of transendothelial migration: new knowledge and new questions. *Cardiovasc Res* 107:310–320. <https://doi.org/10.1093/cvr/cvv145>.
 48. Garcia-Rodas R, Zaragoza O. 2012. Catch me if you can: phagocytosis and killing avoidance by *Cryptococcus neoformans*. *FEMS Immunol Med Microbiol* 64:147–161. <https://doi.org/10.1111/j.1574-695X.2011.00871.x>.
 49. Ma H, Croutace JE, Lammas DA, May RC. 2007. Direct cell-to-cell spread of a pathogenic yeast. *BMC Immunol* 8:15. <https://doi.org/10.1186/1471-2172-8-15>.
 50. Alvarez M, Casadevall A. 2007. Cell-to-cell spread and massive vacuole formation after *Cryptococcus neoformans* infection of murine macrophages. *BMC Immunol* 8:16. <https://doi.org/10.1186/1471-2172-8-16>.
 51. Barchiesi F, Cogliati M, Esposto MC, Spreghini E, Schimizzi AM, Wickes BL, Scalise G, Viviani MA. 2005. Comparative analysis of pathogenicity of *Cryptococcus neoformans* serotypes A, D and AD in murine cryptococcosis. *J Infect* 51:10–16. <https://doi.org/10.1016/j.jinf.2004.07.013>.
 52. Ngamskulrungrroj P, Chang Y, Sionov E, Kwon-Chung KJ. 2012. The primary target organ of *Cryptococcus gattii* is different from that of *Cryptococcus neoformans* in a murine model. *mBio* 3:e00103-12. <https://doi.org/10.1128/mBio.00103-12>.
 53. Charlier C, Chretien F, Baudrimont M, Mordelet E, Lortholary O, Dromer F. 2005. Capsule structure changes associated with *Cryptococcus neoformans* crossing of the blood-brain barrier. *Am J Pathol* 166:421–432. [https://doi.org/10.1016/S0002-9440\(10\)62265-1](https://doi.org/10.1016/S0002-9440(10)62265-1).
 54. Sridhar S, Ahluwalia M, Brummer E, Stevens DA. 2000. Characterization of an anticryptococcal protein isolated from human serum. *Infect Immun* 68:3787–3791. <http://www.ncbi.nlm.nih.gov/pubmed/10816550>.
 55. Zhang M, Sun D, Liu G, Wu H, Zhou H, Shi M. 2016. Real-time in vivo imaging reveals the ability of neutrophils to remove *Cryptococcus neoformans* directly from the brain vasculature. *J Leukoc Biol* 99:467–473. <https://doi.org/10.1189/jlb.4AB0715-281R>.
 56. Carman CV. 2009. Mechanisms for transcellular diapedesis: probing and pathfinding by “invadosome-like protrusions”. *J Cell Sci* 122:3025–3035. <https://doi.org/10.1242/jcs.047522>.
 57. Bojarczuk A, Miller KA, Hotham R, Lewis A, Ogryzko NV, Kamuyango AA, Frost H, Gibson RH, Stillman E, May RC, Renshaw SA, Johnston SA. 2016. *Cryptococcus neoformans* intracellular proliferation and capsule size determines early macrophage control of infection. *Sci Rep* 6:21489. <https://doi.org/10.1038/srep21489>.
 58. Jong A, Wu CH, Gonzales-Gomez I, Kwon-Chung KJ, Chang YC, Tseng HK, Cho WL, Huang SH. 2012. Hyaluronic acid receptor CD44 deficiency is associated with decreased *Cryptococcus neoformans* brain infection. *J Biol Chem* 287:15298–15306. <https://doi.org/10.1074/jbc.M112.353375>.
 59. Samantary S, Correia JN, Garelnabi M, Voelz K, May RC, Hall RA. 2016.

- Novel cell-based in vitro screen to identify small-molecule inhibitors against intracellular replication of *Cryptococcus neoformans* in macrophages. *Int J Antimicrob Agents* 48:69–77. <https://doi.org/10.1016/j.ijantimicag.2016.04.018>.
60. Konradt C, Ueno N, Christian DA, Delong JH, Pritchard GH, Herz J, Bzik DJ, Koshy AA, McGavern DB, Lodoen MB, Hunter CA. 2016. Endothelial cells are a replicative niche for entry of *Toxoplasma gondii* to the central nervous system. *Nat Microbiol* 1:16001. <https://doi.org/10.1038/nmicrobiol.2016.1>.
 61. Santiago-Tirado FH, Peng T, Yang M, Hang HC, Doering TL. 2015. A single protein S-acyl transferase acts through diverse substrates to determine cryptococcal morphology, stress tolerance, and pathogenic outcome. *PLoS Pathog* 11:e1004908. <https://doi.org/10.1371/journal.ppat.1004908>.
 62. Nielsen K, Cox GM, Wang P, Toffaletti DL, Perfect JR, Heitman J. 2003. Sexual cycle of *Cryptococcus neoformans* var. *grubii* and virulence of congeneric α and α isolates. *Infect Immun* 71:4831–4841. <https://doi.org/10.1128/IAI.71.9.4831-4841.2003>.
 63. Liu OW, Chun CD, Chow ED, Chen C, Madhani HD, Noble SM. 2008. Systematic genetic analysis of virulence in the human fungal pathogen *Cryptococcus neoformans*. *Cell* 135:174–188. <https://doi.org/10.1016/j.cell.2008.07.046>.
 64. Tong AH, Evangelista M, Parsons AB, Xu H, Bader GD, Pagé N, Robinson M, Raghizadeh S, Hogue CW, Bussey H, Andrews B, Tyers M, Boone C. 2001. Systematic genetic analysis with ordered arrays of yeast deletion mutants. *Science* 294:2364–2368. <https://doi.org/10.1126/science.1065810>.
 65. Biemans EA, Jäkel L, de Waal RM, Kuiperij HB, Verbeek MM. 2016. Limitations of the hCMEC/D3 cell line as a model for Abeta clearance by the human blood-brain barrier. *J Neurosci Res* <https://doi.org/10.1002/jnr.23964>.
 66. Onken MD, Mooren OL, Mukherjee S, Shahan ST, Li J, Cooper JA. 2014. Endothelial monolayers and transendothelial migration depend on mechanical properties of the substrate. *Cytoskeleton (Hoboken)* 71: 695–706. <https://doi.org/10.1002/cm.21203>.